Tag: Psilocybin

Australian psychedelic medicine company Emyria Limited (ASX: EMD) has been selected by the US Food and Drug Administration (FDA) to ...

BLS Pharmaceuticals Limited (ASX: BLS) has appointed Zivana Crestani as Strategic Partnership Director, adding to the company's commercial leadership as ...

BLS Pharmaceuticals (ASX: BLS) has reported a record FY26, with revenue climbing 161% to $74.2 million and Adjusted EBITDA rising ...

For decades, psychedelic medicine sat on the margins of psychiatry, constrained by international drug controls, political controversy and the legacy ...

A large Australian study of the brain under psilocybin has found evidence of organisation within the neural changes that have ...

Australia's modern psychedelic medicine story is usually traced to the Therapeutic Goods Administration's 2023 decision to allow authorised psychiatrists to ...

The UK’s psychedelic sector is moving into a more commercially significant phase, with late-stage clinical programmes, pharmaceutical investment and changes ...

A new executive order could position the US territory as a research destination for emerging psychedelic therapies as clinicians, researchers ...

New Zealand is building a small but increasingly active psychedelic medicine sector, with clinical psilocybin access, Māori-led research and a ...

Australia's psychedelic medicine industry has crossed the regulatory threshold. Since 1 July 2023, specifically authorised psychiatrists have been able to ...